TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $77.92 million. The enterprise value is $78.21 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 39.55 million shares outstanding. The number of shares has increased by 39.15% in one year.
| Current Share Class | 39.55M |
| Shares Outstanding | 39.55M |
| Shares Change (YoY) | +39.15% |
| Shares Change (QoQ) | +12.96% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 36.13% |
| Float | 18.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.93 |
| Forward PS | 0.85 |
| PB Ratio | 4.30 |
| P/TBV Ratio | 4.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 2.38.
| Current Ratio | 4.22 |
| Quick Ratio | 3.23 |
| Debt / Equity | 2.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.68 |
Financial Efficiency
Return on equity (ROE) is -267.29% and return on invested capital (ROIC) is -41.95%.
| Return on Equity (ROE) | -267.29% |
| Return on Assets (ROA) | -33.34% |
| Return on Invested Capital (ROIC) | -41.95% |
| Return on Capital Employed (ROCE) | -65.49% |
| Revenue Per Employee | $340,751 |
| Profits Per Employee | -$207,866 |
| Employee Count | 209 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.71 |
Taxes
| Income Tax | -92,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.04% in the last 52 weeks. The beta is 0.79, so TELA Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -62.04% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 2.23 |
| Relative Strength Index (RSI) | 64.85 |
| Average Volume (20 Days) | 135,935 |
Short Selling Information
The latest short interest is 569,673, so 1.44% of the outstanding shares have been sold short.
| Short Interest | 569,673 |
| Short Previous Month | 654,637 |
| Short % of Shares Out | 1.44% |
| Short % of Float | 3.05% |
| Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, TELA Bio had revenue of $71.22 million and -$43.44 million in losses. Loss per share was -$1.29.
| Revenue | 71.22M |
| Gross Profit | 48.04M |
| Operating Income | -39.76M |
| Pretax Income | -40.30M |
| Net Income | -43.44M |
| EBITDA | -38.72M |
| EBIT | -39.76M |
| Loss Per Share | -$1.29 |
Full Income StatementBalance Sheet
The company has $42.83 million in cash and $43.12 million in debt, giving a net cash position of -$291,000 or -$0.01 per share.
| Cash & Cash Equivalents | 42.83M |
| Total Debt | 43.12M |
| Net Cash | -291,000 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 18.12M |
| Book Value Per Share | 0.46 |
| Working Capital | 53.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$36.94 million and capital expenditures -$717,000, giving a free cash flow of -$37.65 million.
| Operating Cash Flow | -36.94M |
| Capital Expenditures | -717,000 |
| Free Cash Flow | -37.65M |
| FCF Per Share | -$0.95 |
Full Cash Flow StatementMargins
Gross margin is 67.46%, with operating and profit margins of -55.83% and -61.00%.
| Gross Margin | 67.46% |
| Operating Margin | -55.83% |
| Pretax Margin | -61.13% |
| Profit Margin | -61.00% |
| EBITDA Margin | -54.36% |
| EBIT Margin | -55.83% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.15% |
| Shareholder Yield | -39.15% |
| Earnings Yield | -55.75% |
| FCF Yield | -48.32% |
Analyst Forecast
The average price target for TELA Bio is $6.00, which is 204.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 204.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 24.90% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -5.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.62 |
| Piotroski F-Score | 2 |